Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...
Chip Chick on MSN7mon
The Colorado River Toad Secretes A Potent Poison That Has Psychedelic Properties And May Be Helpful In Treating Anxiety And DepressionThe researchers extracted the poison from the toad’s secretions and used mice to see how it would interact with a serotonin ...
According to the partners, DSP-0038 combines serotonin 5-HT2A receptor antagonism and 5-HT1A receptor agonism – two well established targets for antipsychotic drugs – in a single small molecule.
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous ...
In these women, sublingual testosterone can increase sensitivity to sexual stimuli, and a subsequent dose of a 5-HT1A-receptor agonist then inhibits the sexual-inhibition mechanism. On the basis ...
The drug is a long-acting and potent serotonin 5-HT1A receptor agonist and will be added to DSP’s psychiatry and neurology research pipeline. Paul Workman, chief executive of The Institute of ...
Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL (2007). R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. Bioorg Med Chem Lett 17:4128-4130.
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback